Arbutus Biopharma Corp (ABUS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
William H. Collier
Employees:
90
100-8900 GLENLYON PARKWAY, BURNABY, CANADA V5J 5J8
604-419-3200

Arbutus Biopharma Corporation develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate. AB-836, an oral capsid inhibitor that suppresses HBV DNA replication, is in Phase Ia/Ib clinical trial targeted to hepatocytes.

Data derived from most recent annual or quarterly report
Market Cap 376.282 Million Shares Outstanding148.728 Million Avg 30-day Volume 848.536 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.24
Price to Revenue43.5967 Debt to Equity0.0 EBITDA-55.742 Million
Price to Book Value2.9562 Operating Margin-836.0717 Enterprise Value178.16 Million
Current Ratio13.385 EPS Growth0.654 Quick Ratio13.057
1 Yr BETA 1.0803 52-week High/Low 6.5 / 1.93 Profit Margin-921.9699
Operating Cash Flow Growth27.554 Altman Z-Score-5.8416 Free Cash Flow to Firm -37.252 Million
View SEC Filings from ABUS instead.

View recent insider trading info

Funds Holding ABUS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ABUS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-20:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-08:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-06:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-31:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-26:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-24:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-03:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HENRIQUES RICHARD C JR

    • Director
    41,000 2022-05-25 1

    BURGESS DANIEL D

    • Director
    41,000 2022-05-25 1

    MANCHESTER KEITH S

    • Director
    41,000 2022-05-25 1

    MEYERS JAMES R

    • Director
    41,000 2022-05-25 1

    TORTI FRANK

    • Director
    41,000 2022-05-25 1

    TRAN TRAM

    • Director
    41,000 2022-05-25 3

    HASTINGS DAVID C CHIEF FINANCIAL OFFICER

    • Officer
    285,000 2022-01-20 1

    SOFIA MICHAEL J. CHIEF SCIENTIFIC OFFICER

    • Officer
    285,000 2022-01-20 2

    MCELHAUGH MICHAEL J. CHIEF BUSINESS OFFICER

    • Officer
    325,850 2022-01-20 1

    HOWARD ELIZABETH CHIEF COMPLIANCE OFFICER

    • Officer
    237,500 2022-01-20 1

    PICCHIO GASTON CHIEF DEVELOPMENT OFFICER

    • Officer
    256,500 2022-01-20 1

    COLLIER WILLIAM H. PRESIDENT AND CEO

    • Officer
    • Director
    787,550 2022-01-20 1

    ROIVANT SCIENCES LTD.

    • 10% Owner
    38,847,462 2021-10-18 1

    CHENG ANDREW

    • Director
    22,000 2021-06-03 0

    VENKER ERIC

    • Director
    0 2020-02-18 0

    POTTER MYRTLE S

    • Director
    0 2019-08-17 0

    VIKING GLOBAL PERFORMANCE LLC

    VIKING GLOBAL EQUITIES LP

    VIKING GLOBAL EQUITIES II LP

    VGE III PORTFOLIO LTD.

    VIKING GLOBAL EQUITIES MASTER LTD.

    VIKING LONG FUND GP LLC

    VIKING LONG FUND MASTER LTD.

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    No longer subject to file 2019-07-10 0

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    No longer subject to file 2019-07-10 0

    QVT ASSOCIATES GP LLC

    QVT FUND V LP

    • Director
    • 10% Owner
    • SEE REMARKSSEE REMARKS
    No longer subject to file 2019-07-10 0

    MACHADO PATRICK

    • FORMER 10% OWNER
    No longer subject to file 2019-07-10 0

    DEXXON HOLDINGS LTD.

    DEXCEL PHARMA TECHNOLOGIES LTD.

    OREN DAN

    • SEE REMARKSSEE REMARKSSEE REMARKS
    No longer subject to file 2019-07-10 0

    LO ANDREW

    • FORMER 10% OWNER
    No longer subject to file 2019-07-10 0

    SVF INVESTMENTS (UK) LTD

    SOFTBANK VISION FUND L.P.

    SVF HOLDINGS (UK) LLP

    SVF GP (JERSEY) LTD

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    No longer subject to file 2019-07-10 0

    MURRAY MARK J. PRESIDENT AND CEO

    • Officer
    • Director
    0 2019-03-01 0

    VIKING GLOBAL EQUITIES MASTER LTD.

    • 10% Owner
    16,013,540 2019-01-01 0

    VANDENENDEN KOERT CHIEF ACCOUNTING OFFICER

    • Officer
    0 2018-12-11 0

    CONRAD HERBERT J

    • Director
    0 2018-06-19 0

    RAMASWAMY VIVEK

    • Director
    0 2018-06-19 0

    SYMONDS WILLIAM T. CHIEF DEVELOPMENT OFFICER

    • Officer
    0 2018-04-16 0

    LUTWYCHE PETER FORMER CHIEF TECH. OFFICER

    • Officer
    No longer subject to file 2018-04-11 0

    COUSINS BRUCE EXEC VO & CFO

    • Officer
    No longer subject to file 2018-02-16 0

    VIKING GLOBAL PERFORMANCE LLC

    VIKING GLOBAL EQUITIES LP

    VIKING GLOBAL EQUITIES II LP

    VGE III PORTFOLIO LTD.

    VIKING LONG FUND MASTER LTD.

    VIKING LONG FUND GP LLC

    • 10% Owner
    0 2018-01-12 0

    DEXCEL PHARMA TECHNOLOGIES LTD.

    • 10% Owner
    16,013,540 2017-09-06 0

    SHABET ROSE SHARON

    • 10% Owner
    16,013,540 2017-07-01 0

    KARBE FRANK

    • Director
    0 2017-06-21 0

    ABRAMS MICHAEL J. MANAGING DIRECTOR

    • Officer
    No longer subject to file 2016-09-30 0

    KOWALSKI MARK SR VP & CHIEF MEDICAL OFFICER

    • Officer
    No longer subject to file 2016-09-30 0

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SUNDHEIM DANIEL S.

    • 10% Owner
    16,013,540 2016-07-08 0

    DEXXON HOLDINGS LTD.

    OREN DAN

    • 10% Owner
    16,013,540 2016-07-08 0

    HIGGINS PATRICK T. CHIEF BUSINESS OFFICER

    • Officer
    No longer subject to file 2016-04-30 0

    KISNER DANIEL L

    • FORMER DIRECTOR
    No longer subject to file 2015-03-04 0

    PHILLIPS PEGGY V

    • FORMER DIRECTOR
    No longer subject to file 2015-03-04 0

    BRENNAN PAUL A. SR VP, BUSINESS DEVELOPMENT

    • Officer
    No longer subject to file 2015-03-04 0

    GARDINER DIANE

    • FORMER VP, HUMAN RESOURCES
    No longer subject to file 2015-03-04 0

    JEWELL DONALD GORDON

    • FORMER DIRECTOR
    No longer subject to file 2015-03-04 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 22:15:04 UTC 1.5658 0.7542 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 21:45:03 UTC 1.5658 0.7542 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 21:15:03 UTC 1.5658 0.7542 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 20:45:04 UTC 1.5658 0.7542 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 20:15:05 UTC 1.5658 0.7542 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 19:45:04 UTC 1.5658 0.7542 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 19:15:05 UTC 1.5658 0.7542 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 18:45:04 UTC 1.5658 0.7542 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 18:15:03 UTC 1.5658 0.7542 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 17:45:04 UTC 1.5658 0.7542 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 17:15:04 UTC 1.5658 0.7542 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 16:45:05 UTC 1.5587 0.7613 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 16:15:05 UTC 1.5587 0.7613 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 15:45:04 UTC 1.5587 0.7613 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 15:15:03 UTC 1.5587 0.7613 6300000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 14:45:04 UTC 1.5587 0.7613 6300000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 14:15:04 UTC 1.5587 0.7613 6300000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 13:45:05 UTC 1.5585 0.7615 6300000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 13:15:04 UTC 1.5585 0.7615 6400000
    ARBUTUS BIOPHARMA CORP ABUS 2022-08-05 12:45:05 UTC 1.5585 0.7615 6400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments